Indeed, higher rates of plasmin-dependent activation of cancer-derived TGF-β would then dose-dependently contribute to increased secretion of PAI1 [18] to constrain excessive TGF-β signalling in the tumour microenvironment, although at the cost of increased risk of thrombotic events. This evidence concerns the gene TGFB1 and cancer.